Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada
- 1 May 2012
- journal article
- Published by Elsevier BV in Value in Health
- Vol. 15 (3), 580-585
- https://doi.org/10.1016/j.jval.2011.12.006
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- National assessment of cancer drugs commencesCMAJ : Canadian Medical Association Journal, 2011
- When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in OncologyJNCI Journal of the National Cancer Institute, 2010
- Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trialsInternational Journal of Clinical Oncology, 2009
- Progression-free survival as a surrogate endpoint in advanced breast cancer.International Journal of Technology Assessment in Health Care, 2008
- Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspectiveStatistical Methods in Medical Research, 2008
- Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancerStatistical Methods in Medical Research, 2008
- Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006Annals of Oncology, 2007
- Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and FutureJournal of Clinical Oncology, 2007
- Methodological issues in the economic analysis of cancer treatmentsEuropean Journal of Cancer, 2006
- Improving the efficiency of clinical trials: A medical perspectiveStatistics in Medicine, 1984